All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

64Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PET Imaging in Prostate Cancer

August 27th 2024

The FDA has granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions.

Early Data for OMX-0407 Fuel Expansion Cohorts in RCC, Angiosarcoma

August 27th 2024

OMX-0407 was safe and displayed activity in advanced solid tumors; dose-expansion cohorts will evaluate the agent in RCC and angiosarcoma.

Biomarker-Driven Approaches Could Refine Treatment Selection in RCC

August 26th 2024

Emre Yekedüz, MD, discusses the exploration of biomarker-driven therapeutic approaches in renal cell carcinoma.

Treatment Advances Underscore Need for MMR/MSI Testing in Advanced Endometrial Cancer

August 26th 2024

Bhavana Pothuri, MD, discusses real-world testing patterns for MMR/MSI status in patients with advanced endometrial cancer.

Time-Limited Bispecific Antibodies Could Represent Next Shift in Myeloma Treatment

August 26th 2024

Rahul Banerjee MD, FACP, discusses the rapidly evolving therapeutic landscape of bispecific antibodies in the treatment of patients with multiple myeloma.

Lewis Katz School of Medicine at Temple University and Fox Chase Cancer Center Researcher Receives Grant to Explore Chemotherapy’s Role in Cancer Relapse

August 26th 2024

Lucia Borriello, PhD, an Assistant Professor at the Lewis Katz School of Medicine at Temple University and Fox Chase Cancer Center, has received a $150,000 grant to explore chemotherapy’s role in cancer relapse.

FDA Grants Fast Track Designation to BGB-16673 in Previously Treated CLL/SLL

August 26th 2024

BGB-16673 has received FDA fast track designation for relapsed or refractory CLL or SLL following 2 or more prior lines of therapy.

EU Greenlights Odronextamab for R/R Follicular Lymphoma and DLBCL

August 26th 2024

The European Commission approved odronextamab for patients with relapsed/refractory FL or DLBCL who have received at least 2 prior lines of therapy.

DESTINY-Breast06 Redefines Treatment Paradigms, Calls Necessity of HER2 Testing for T-DXd into Question in HR+ Breast Cancer

August 26th 2024

Jason A. Mouabbi, MD, discusses shifting standards for HER2 testing for T-DXd administration and areas of ongoing ADC development within breast cancer.

CDK4/6 Inhibitors, ADCs, and PI3K Inhibitors Individualize HR+ Breast Cancer Management

August 26th 2024

Shipra Gandhi, MD, discusses the evolution of CDK4/6 inhibitors and ADCs across breast cancer subtypes.

PARP Inhibitors and ADCs Spark Change Across Ovarian and Cervical Cancer Paradigms

August 26th 2024

Ritu Salani, MD, discusses the role of ADCs in ovarian cancer and what the future of the post-IO setting in cervical cancer management may look like.

NSABP B-51 Data Highlight Evolving Role of Radiation in Early-Stage Breast Cancer

August 25th 2024

Bruce G. Haffty, MD, MS, discusses radiation therapy in node-positive breast cancer that becomes node negative after neoadjuvant chemotherapy.

DREAMM-7 and DREAMM-8 Data Support Belantamab Mafodotin–Based Combos in R/R Myeloma

August 24th 2024

Suzanne Trudel, MSc, MD, discusses updated data from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin–based regimens in R/R multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 8/18

August 24th 2024

A frontline doublet receives FDA approval in EGFR+ NSCLC, a CRL is issued to linvoseltamab in multiple myeloma, and more this week from OncLive.

Dostarlimab Plus Chemotherapy Opens Doors Across Endometrial Cancer Subtypes

August 23rd 2024

Krishnansu S. Tewari, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

INV724 Earns FDA Rare Pediatric Disease, Orphan Drug Designations for Neuroblastoma

August 23rd 2024

The FDA has awarded rare pediatric disease designation and orphan drug designation to INV724 for the treatment of neuroblastoma.

Final Results of Phase 2 Clinical Trial Clarify Role of JAK2 Inhibitor in Combating Acute Graft-Versus-Host Disease

August 23rd 2024

A study demonstrates that adding a JAK2 inhibitor to standard immunosuppressive drugs does not improve prevention of acute graft-versus-host disease.

Erdafitinib Wins EU Approval for FGFR3+ Unresectable, Metastatic Urothelial Carcinoma

August 23rd 2024

Erdafitinib was approved by the European Commission for pretreated unresectable or metastatic urothelial carcinoma harboring FGFR3 alterations.

FDA Grants Fast Track Designation to Neoadjuvant APG-157 for Head and Neck Cancer

August 23rd 2024

The FDA has granted fast track designation to APG-157 for the neoadjuvant treatment of head and neck cancer.

Tepotinib Plus Osimertinib Demonstrates Activity in EGFR+ NSCLC

August 23rd 2024

Data from the INSIGHT 2 study showed that tepotinib plus osimertinib elicited responses in patients with EGFR-mutated non–small cell lung cancer.